UroGen Pharma (URGN) Expected to Announce Quarterly Earnings on Monday

UroGen Pharma (NASDAQ:URGN - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.83) per share and revenue of $22.71 million for the quarter.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Trading Up 4.5 %

Shares of NASDAQ:URGN traded up $0.43 during trading on Wednesday, reaching $10.12. 818,153 shares of the stock were exchanged, compared to its average volume of 538,825. The firm has a market cap of $466.74 million, a price-to-earnings ratio of -3.21 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a 12-month low of $8.94 and a 12-month high of $20.70. The firm's 50-day moving average price is $10.60 and its 200 day moving average price is $11.02.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on URGN. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. The Goldman Sachs Group lowered their target price on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Monday, April 28th. Scotiabank assumed coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a report on Tuesday, April 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $32.86.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.